Paul W Rothlauf

9PUBLICATIONS
134CO-AUTHORS
TransgenesisMedical infection agents (incl. prions)Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Proteins and peptides
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 04, 2026
CD164 is an endolysomal host factor for entry of Clade A New World Arenaviruses.

|Oct 30, 2025
Multiple LDLR family members act as entry receptors for yellow fever virus.

Zhenlu Chong, Sean Hui, Xueer Qiu

|Oct 01, 2024
Endosomal fusion of pH-dependent enveloped viruses requires ion channel TRPM7.

Catherine A Doyle, Gregory W Busey, Wesley H Iobst

|Apr 01, 2022
Defining the risk of SARS-CoV-2 variants on immune protection.

Marciela M DeGrace, Elodie Ghedin, Matthew B Frieman

|Oct 16, 2021
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.

Novalia Pishesha, Thibault J Harmand, Paul W Rothlauf

|Oct 12, 2021
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.

Matthew Mahoney, Vishnu C Damalanka, Michael A Tartell

Pageof 2